Vasodilators inhibit acute alpha 1-adrenergic receptor-induced trophic responses in the vasculature

K E Thompson1, P Friberg, M A Adams

  • 1Department of Pharmacology and Toxicology, Queen's University, Kingston, Ontario, Canada.

Insights

Alpha 1-adrenergic receptor activation increases blood pressure and vascular ornithine decarboxylase (ODC) activity. Vasodilators reduce both effects, suggesting blood pressure elevation is key to ODC induction in vascular hypertrophy.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Pharmacology

Background:

  • Cardiovascular hypertrophy is linked to hypertension development.
  • Sympathetic nervous system hyperactivity may drive structural changes in hypertension.
  • Ornithine decarboxylase (ODC) is an early marker of cellular growth.

Purpose of the Study:

  • To investigate if alpha 1-adrenergic receptor-induced vascular growth responses depend on elevated arterial pressure.
  • To assess the role of blood pressure in mediating ODC induction by alpha 1-adrenergic stimulation.

Main Methods:

  • Administered methoxamine (alpha 1-adrenergic agonist) to rats to induce hypertension and ODC activity.
  • Co-administered vasodilators (hydralazine or felodipine) with methoxamine to control mean arterial pressure (MAP).
  • Measured changes in MAP and vascular ODC activity in aorta and mesenteric vasculature.

Main Results:

  • Methoxamine dose-dependently increased MAP and vascular ODC activity.
  • Concomitant administration of vasodilators attenuated methoxamine-induced MAP increases and ODC activation.
  • A strong correlation was observed between MAP elevation and ODC activation in mesenteric and aortic vasculature.

Conclusions:

  • Alpha 1-adrenergic receptor activation stimulates vascular ODC activity, a marker of cellular growth, in conjunction with elevated blood pressure.
  • Vasodilators inhibit both the pressor response and ODC activation induced by alpha 1-adrenergic stimulation.
  • Elevated arterial pressure is a critical factor in the alpha 1-adrenergic receptor-mediated induction of vascular ODC.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...